Conquering Diseases

A Study Comparing Investigational Drug With An Already Approved Drug For Advanced Or Recurrent Endometrial Cancer


Seeking women at least 18 years of age with confirmed or recurrent endometrial cancer for study of an investigational drug


We are studying the effect of a investigational drug called Pembrolizumab compared to Platinum Doublet Chemotherapy in patients with recurrent endometrial cancer.

What we're hoping for

Evaluate the safety, tolerablity, and how well Pembrolizumab works compared to Platinum Doublet Chemotherapy.

Additional Information Identifier: NCT05173987

 Principal Investigator

Susan  Zweizig, MD

UMass Memorial Health

 Study Contact

The Cancer  Research Office



UMass Chan University Campus

55 Lake Ave North 

Worcester,MA 01655